TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases.
Immunotherapy
; 13(13): 1135-1150, 2021 09.
Article
em En
| MEDLINE
| ID: mdl-34235974
ABSTRACT
JAKs are intracellular protein tyrosine kinases that, through activation of STATs, are responsible for signal transduction pathways that regulate cellular responses to numerous cytokines, growth factors and hormones in many different cells. JAK-STAT signaling plays a key role in regulating immune function, and cytokines - such as IL-23, IL-12 and type I interferons - are central to the pathogenesis of autoimmune diseases, including psoriasis, inflammatory bowel disease and systemic lupus erythematosus. Here the authors review the evidence for targeting TYK2 as a more specific approach to treating these conditions. TYK2 inhibitors are clinically effective in autoimmune and inflammatory diseases and may avoid some of the complications reported with nonselective JAK inhibitors.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças Autoimunes
/
Doenças Inflamatórias Intestinais
/
TYK2 Quinase
/
Imunoterapia
/
Lúpus Eritematoso Sistêmico
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article